Randomized Controlled Trial of Clopidogrel plus Aspirin to Prevent Hemodialysis Access Graft Thrombosis
Authors:
- James S. KaufmanJKJames S. Kaufman
- Theresa Z. O’cOnnorTOTheresa Z. O’cOnnor
- Jane Hongyuan ZhangJZJane Hongyuan Zhang
- Robert E. CroninRCRobert E. Cronin
- Louis D. FioreLFLouis D. Fiore
- Michael B. GanzMGMichael B. Ganz
- David S. GoldfarbDGDavid S. Goldfarb
- Peter N. PeduzziPPPeter N. Peduzzi
- 1 September 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 14 (9) , 2313-2321
Abstract
Thrombosis of hemodialysis vascular access grafts represents a major medical and economic burden. Experimental and clinical models suggest a role for antiplatelet agents in the prevention of thrombosis. The study was designed to determine the efficacy of the combination of aspirin and clopidogrel in the prevention of graft thrombosis. The study was a randomized, double-blind trial conducted at 30 hemodialysis units at Veterans Affairs medical centers. Participants undergoing hemodialysis with a polytetrafluoroethylene graft in the arm were randomized to receive either double placebos or aspirin (325 mg) and clopidogrel (75 mg) daily. Participants were to be monitored while receiving study medications for a minimum of 2 yr. The study was stopped after randomization of 200 participants, as recommended by the Data Safety and Monitoring Board because of a significantly increased risk of bleeding among the participants receiving aspirin and clopidogrel therapy. The cumulative incidence of bleeding events was significantly greater for those participants, compared with participants receiving placebos [hazard ratio, 1.98; 95% confidence interval (CI), 1.19 to 3.28; P = 0.007]. Twenty-three participants in the placebo group and 44 participants in the active treatment group experienced a bleeding event (P = 0.006). There was no significant benefit of active treatment in the prevention of thrombosis (hazard ratio, 0.81; 95% CI, 0.47 to 1.40; P = 0.45), although there was a trend toward a benefit among participants who had not experienced previous graft thrombosis (hazard ratio, 0.52; 95% CI, 0.22 to 1.26; P = 0.14). In the hemodialysis population, therapy with aspirin and clopidogrel was associated with a significantly increased risk of bleeding and probably would not result in a reduced frequency of graft thrombosis. E-mail: james.kaufman@med.va.govKeywords
This publication has 22 references indexed in Scilit:
- Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosisKidney International, 2002
- Venous neointimal hyperplasia in polytetrafluoroethylene dialysis graftsKidney International, 2001
- III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: Update 2000American Journal of Kidney Diseases, 2001
- Vascular access for hemodialysisKidney International, 1999
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery StentingNew England Journal of Medicine, 1998
- Linear Transformations of Linear Mixed-Effects ModelsThe American Statistician, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Percutaneous transvenous angioplasty in the treatment of vascular access stenosisKidney International, 1992
- MODERATE DOSES OF ASPIRIN AND RISK OF BLEEDING IN RENAL FAILUREThe Lancet, 1986
- Prevention of Thrombosis in Patients on Hemodialysis by Low-Dose AspirinNew England Journal of Medicine, 1979